RTP Mobile Logo
Recent Advances in Medical Oncology: Colorectal and Gastric Cancer (Webinar Audio Proceedings)
Released November 2020

Featuring perspectives from Drs Johanna Bendell, Crystal Denlinger and Axel Grothey. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

    LEARNING OBJECTIVES

    • Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer (mCRC), considering the patient’s biomarker profile (BRAF, MSI, HER2 status), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
    • Appreciate published research data with and the FDA approval of encorafenib in combination with cetuximab for patients with relapsed/refractory CRC and a BRAF-V600E mutation to optimally incorporate this therapeutic strategy into current clinical algorithms.
    • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection and sequence of systemic therapy for patients with locally advanced or metastatic gastric/gastroesophageal cancer.
    • Recall the biologic rationale for and available data with the use of trastuzumab deruxtecan for patients with previously treated HER2-positive CRC or gastric/gastroesophageal cancers, and discern the current and potential future clinical applicability of this treatment strategy.
    • Evaluate available data with anti-PD-1 and anti-CTLA-4 antibodies for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) mCRC, and appropriately integrate these agents into current treatment algorithms.
    • Consider the recent FDA approval of pembrolizumab as first-line therapy for patients with MSI-H/dMMR mCRC and counsel appropriate individuals regarding personalized treatment recommendations.
    • Describe ongoing research to validate the potential benefit of immune checkpoint inhibitors in combination with chemotherapy, targeted therapy or other immunotherapies for patients with MSI-H/dMMR and MSI-stable mCRC, and use this information to guide trial design and referral.
    • Devise a rational approach to the incorporation of TAS-102 into the treatment algorithms for previously treated locally advanced or mCRC or gastric/gastroesophageal cancers.
    • Recall new data with investigational agents demonstrating promising activity in gastrointestinal cancers, and use this information to refer appropriate patients for participation in ongoing trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Johanna Bendell, MD
    Chief Development Officer
    Director, Drug Development Unit Nashville
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Advisory Committee and Consulting Agreements (to Institution): Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Piper Biotech, Prelude Therapeutics, Relay Therapeutics, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Research Funding to Institution: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Therapeutics, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, Bayer HealthCare Pharmaceuticals, Beigene, Bellicum Pharmaceuticals Inc, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, CALGB, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceutical Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Morphotek Inc, Nektar, NGM Biopharmaceuticals, Novartis, Novocure, Numab Therapeutics, OncoGenex Pharmaceuticals Inc, Oncologie, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Relay Therapeutics, Revolution Medicines, Rgenix, Sanofi Genzyme, Scholar Rock, Seagen Inc, Shattuck Labs, Sierra Oncology, Stemcentrx, SynDevRx Inc, Synthorx, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad, Zymeworks.

    Crystal Denlinger, MD
    Chief, GI Medical Oncology
    Director, Survivorship Program
    Deputy Director, Phase 1 Program
    Associate Professor, Department of Hematology/Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: Astellas, Exelixis Inc; Consulting Agreements: Bristol-Myers Squibb Company, Merck; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Bristol-Myers Squibb Company, Exelixis Inc, Lilly, MacroGenics Inc, Sanofi Genzyme, Zymeworks.

    Axel Grothey, MD
    Director, GI Cancer Research
    West Cancer Center and Research Institute
    Chair, OneOncology Research Network
    OneOncology
    Germantown, Tennessee

    Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Taiho Oncology Inc, Takeda Oncology; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals (now Sumitomo Dainippon Pharma Oncology Inc), Celgene Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Grail Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, and Taiho Oncology Inc.

    Release date: November 2020
    Expiration date: November 2021

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):